Lymphoma, Large B-Cell, Diffuse
Showing 1 - 25 of >10,000
Molecular Classification of Relapsed/Refractory Diffuse Large
Completed
- Lymphoma, Large B-Cell, Diffuse
- Gene Expression Profiling
- Gene expression profile
-
Shanghai, Shanghai, ChinaYian Zhang
Mar 31, 2022
Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +4 more
- (no location specified)
Mar 9, 2023
Lymphoma, Large B-Cell, Diffuse, Fatigue Trial in Columbus (Fatigue Reduction Diet)
Completed
- Lymphoma, Large B-Cell, Diffuse
- Fatigue
- Fatigue Reduction Diet
-
Columbus, OhioThe Ohio State University
Apr 26, 2022
Chidamide in Recurrent and Refractory Diffuse Large b
Enrolling by invitation
- Diffuse Large B-cell Lymphoma
- Chidamide
- +2 more
-
Suzhou, Jiangsu, ChinaSecond Affiliated Hospital of Soochow University
Jan 9, 2023
Relapsed/Refractory Diffuse Large B Cell Lymphoma Trial in Seoul (Glofitamab, Poseltinib, Lenalidomide)
Recruiting
- Relapsed/Refractory Diffuse Large B Cell Lymphoma
- Glofitamab, Poseltinib, Lenalidomide
-
Seoul, Korea, Republic ofSeoul National University Hospital
May 30, 2022
DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- High-grade B-cell Lymphoma
- Loncastuximab Tesirine
- (no location specified)
Dec 13, 2022
Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +7 more
- (no location specified)
Mar 23, 2023
Relapsed Diffuse Large B-cell Lymphoma Trial in Detroit (loncastuximab tesirine)
Recruiting
- Relapsed Diffuse Large B-cell Lymphoma
- loncastuximab tesirine
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Jun 24, 2022
Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation
Recruiting
- Lymphoma, Large B-Cell, Diffuse
-
Copenhagen, DenmarkDepartment of Hematology, Rigshospitalet
Jan 12, 2022
Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)
Recruiting
- Diffuse Large B Cell Lymphoma
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
May 4, 2022
Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy Trial (ultra-fraction radiotherapy)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- +3 more
- ultra-fraction radiotherapy
- (no location specified)
Aug 22, 2022
Lymphoma, Large B-Cell, Diffuse Trial in Saint Louis, Columbus (Brentuximab vedotin, Lenalidomide)
Completed
- Lymphoma, Large B-Cell, Diffuse
- Brentuximab vedotin
- Lenalidomide
-
Saint Louis, Missouri
- +1 more
Feb 16, 2022
Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Epcoritamab
- Lenalidomide
- (no location specified)
Jan 20, 2023
Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma
Completed
- Diffuse Large B-cell Lymphoma (DLBCL)
- CAR-T
- Allo-HSCT cohort
-
East Hanover, New JerseyNovartis Investigative Site
Jun 29, 2022
Diffuse Large B Cell Lymphoma Trial in Tampa (Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy)
Recruiting
- Diffuse Large B Cell Lymphoma
- Itacitinib
- Chimeric antigen receptor (CAR) T-cell therapy
-
Tampa, FloridaMoffitt Cancer Center
Mar 6, 2023
Diffuse Large B Cell Lymphoma Trial (Rituximab, Cyclophosphamide, Doxorubicin)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Rituximab
- +7 more
- (no location specified)
Apr 24, 2022
Diffuse Large B Cell Lymphoma Trial (anti-CD19 CAR NK cells)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- anti-CD19 CAR NK cells
- (no location specified)
Dec 21, 2022
Large B-Cell Lymphoma, DLBCL Trial (Tafasitamab, Lenalidomide)
Not yet recruiting
- Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- (no location specified)
Jun 17, 2022
Diffuse Large B Cell Lymphoma,DLBCL Trial in Chengdu (PM 8.4 mg/m2, PM 11.2 mg/m2)
Recruiting
- Diffuse Large B Cell Lymphoma,DLBCL
- PM 8.4 mg/m2
- PM 11.2 mg/m2
-
Chengdu, Sichuan, ChinaWest China Hospital Sichuan University
Jan 15, 2023
Diffuse Large B-cell Lymphoma Trial in Wuhan (Mitoxantrone Hydrochloride Liposome, Rituximab, Lenalidomide)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Mitoxantrone Hydrochloride Liposome
- +2 more
-
Wuhan, Hubei, ChinaDepartment of Hematology Tongji Hospital, Tongji Medical College
Oct 7, 2022
18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma
Completed
- Lymphoma, Large B-Cell, Diffuse
- FDG PET radiomic feature evaluation
-
Hangzhou, Zhejiang, ChinaSecond Affiliated Hospital, School of Medicine, Zhejiang Univers
Sep 27, 2021
Diffuse Large B Cell Lymphoma Trial in Shanghai (zanubrutinib)
Recruiting
- Diffuse Large B Cell Lymphoma
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 13, 2022
Diffuse Large B Cell Lymphoma Trial in Wenzhou (Zanubrutinib+Rituximab+Lenalidomide, RCHOP/RCDOP)
Recruiting
- Diffuse Large B Cell Lymphoma
-
Wenzhou, Zhejiang, ChinaFirst Affiliated Hospital of Wenzhou Medical University
Jun 20, 2022
Resistance to GNC-038 in Relapsed and Refractory Diffuse Large
Recruiting
- Diffuse Large B Cell Lymphoma
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Apr 17, 2022
Tisagenlecleucel in Brazilian Acute Lymphoblastic Leukemia or
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Acute Lymphoblastic Leukemia
- tisagenlecleucel
- (no location specified)
Sep 13, 2022